Evaluating the Inhibitory Effects of Colchicine and Propranolol on Toxoplasma gondii Entrance into Host Cells in vitro and in vivo

Document Type : Original Research

Authors
A. Daryani 1
M. A. Ebrahimzadeh 2
A. S. Pagheh 3
M. Sharif 1
S. Sarvi 1
E. Ahmadpour 4
S. Aghayan 5
F. Rezaei 6
1 Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran
2 Pharmaceutical Sciences Research Center, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
3 Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran
4 Drug Applied Research center, Tabriz University of Medical Sciences, Tabriz, Iran
5 Laboratory of Zoology, Research Institute of Biology, Yerevan State University, Yerevan, Republic of Armenia.
6 Islamic Azad University of Chalus Branch, Chalus, Iran
10.52547/iem.8.3.251
Abstract
Backgrounds: Toxoplasma gondii is a zoonotic parasite of increasing concern to humans and animals. Considering the side effects of drugs used to treat toxoplasmosis, it is essential to find alternative drugs.

Materials & Methods: In this study, colchicine and propranolol at four concentrations (1, 5, 10, and 15 µg/mL) were added to the RPMI medium containing peritoneal macrophages and incubated for 60 min, Then tachyzoites were added to the medium, and the efficacy rates of colchicine and propranolol in inhibiting tachyzoites entry into macrophages were evaluated after 30 and 60 min. For in vivo assay, one group received no drugs, and the second group was treated with colchicine and propranolol at different concentrations for different durations.

Findings: The in vitro experiment showed that treatment with 15 mg/mL of colchicine and propranolol for 60 min following tachyzoites addition was the most efficient method to inhibit tachyzoites penetration, indicating the efficacy rates of 80.20%±1.20 and 89.97%±1.30, respectively (p< .05). Based on the in vivo test, pretreatment with 2 mg/kg of colchicine one hour before tachyzoites injection had the best inhibitory effect (70.32%±4.07). Also, pretreatment with 2 mg/kg of propranolol 90 min before tachyzoites injection (78.54%±1.99) induced the best inhibitory effect (p< .05).

Conclusion: According to the results, colchicine and propranolol could inhibit tachyzoites entrance into nucleated cells in vitro and in vivo. In this study, the most efficient concentrations and times for using these substances were determined.

Keywords

Subjects

1. Tenter AM, HeckerothAR, WeissLM.Toxoplasma gondii: from animals to humans. Int J Parasitol. 2000 Nov; 30(12-13): 1217–1258.
2.Safarpour H, Cevik M, Zarean M, Barac A, Hatam-Nahavandi K, Rahimi MT, et al. Global status of Toxoplasma gondii infection and associated risk factors in people living with HIV.AIDS. 2020; 34 [3]: 469-474.
3. Wyrosdick HM, Schaefer JJ.Toxoplasma gondii: history and diagnostic test development. AnimHealth ResRev. 2015;16 [2]:150-162.
4.Foroutan-Rad M, Majidiani H, Dalvand S, Daryani A, Kooti W, Saki J, et al. Toxoplasmosis in blood donors: a systematic review and meta-analysis. TransfusMedRev.2016;30[3]:116-122.
5. Rezaei F, Sharif M, Sarvi S, Hejazi SH, Aghayan S, Pagheh AS, Dodangeh S, Daryani A. A systematic review on the role of GRA proteins of Toxoplasma gondiiin host immunization. J Microbiol Methods. 2019:105696.
6. Al Nasr I, Ahmed F, Pullishery F, El-Ashram S, Ramaiah VV. Toxoplasmosis and anti-Toxoplasma effects of medicinal plant extracts-A mini-review. Asian Pac JTropMed.2016;9[8]:730-734.
7. Iaccheri B, Fiore T, Papadaki T, Androudi S, Janjua S, Bhaila I, Foster CS. Adverse drug reactions to treatments for ocular toxoplasmosis: a retrospective chart review. ClinTher.2008;30 (11):2069-2074.
8. Araujo FG, Remington JS. Recent advances in the search for new drugs for treatment of toxoplasmosis. IntJAntimicrob Agents.1992;1[4]:153-164.
9. Teil J, Dupont D, Charpiat B, Corvaisier S, Vial T, Leboucher G, Wallon M, Peyron F. Treatment of congenital toxoplasmosis: safety of the sulfadoxine–pyrimethamine combination in children based on a method of causality assessment. PediatrInfectDisJ.2016;35[6]:634-638.
10.Antczak M, Dzitko K, Długońska H. Human toxoplasmosis–Searching for novel chemotherapeutics. Biomed Pharmacother. 2016;82:677-684.
11. Konstantinovic Neda, GueganH, StäjnerT, BelazS, Robert-GangneuxbF. Treatment of toxoplasmosis: Current options and future perspectives. Food Waterborne Parasitol. 2019; 15: e00036.
12. Petersen E, Schmidt DR. Sulfadiazine and pyrimethamine in the postnatal treatment of congenital toxoplasmosis: what are the options?. Expert RevAnti-infectTher.2003;1[1]:175-182.
13. Montazeri M, Emami S, Asgarian-Omran H, Azizi S, Sharif M, Sarvi S, Rezaei F, Sadeghi M, Gohardehi S, Daryani A: In vitro and in vivo evaluation of kojic acid against Toxoplasma gondii in experimental models of acute toxoplasmosis. Exp Parasitol. 2019;200:7-12.
14. Joiner K A, Fuhrman S A, MiettinenH M, KasperL H, Mellman I. Toxoplasma gondii: fusion competence of parasitophorous vacuoles in Fc receptor-transfected fibroblasts.Science. 1990;10;249(4969):641-6.
15. Cortez E, Stumbo AC, Oliveira M, Barbosa HS, Carvalho L. Statins inhibit Toxoplasma gondii multiplication in macrophages in vitro. Int J Antimicrob Agents.2009;33 [2]:185-186.
16. Rezaei F, Ebrahimzadeh MA, Daryani A, Sharif M, Ahmadpour E, Sarvi S. The inhibitory effect of cromolyn sodium and ketotifen on Toxoplasma gondii entrance into host cells in vitro and in vivo. J Parasit Dis. 2016;40:1001-1005.
17. Daryani A, Ebrahimzadeh M-A, Sharif M, Rezaei F, Ahmadpour E, Sarvi S, et al. The inhibitory effect of ketotifen on entrance of Toxoplasma gondii tachyzoites into macrophages of mouse. J Maz Univ Med Sci. 2014;23:75-80.
18. Montazeri M, Daryani A, Ebrahimzadeh M, Ahmadpour E, Sharif M, Sarvi S. Effect of propranolol alone and in combination with pyrimethamine on acute murine toxoplasmosis. Jundishapur JMicrobiol.2015;8[9]: e22572.
19. D'angelo JG, Bordon C, Posner GH, Yolken R, Jones-Brando L. Artemisinin derivatives inhibit Toxoplasma gondii in vitro at multiple steps in the lytic cycle. J.Antimicrob. Chemother.2008;63[1]:146-150.
20. Ohnishi ST, Sadanaga KK, Katsuoka M, Weidanz WP. Effects of membrane acting-drugs on plasmodium species and sickle cell erythrocytes. MolCellBiochem.1989;91[1-2]:159-165.
21. Ryning FW, Remington JS. Effect of cytochalasin D on Toxoplasma gondii cell entry. Infect.Immun.1978;20 [3]:739-743.
22. Morejohn L, Bureau T, Mole-Bajer J, Bajer A, Fosket D. Oryzalin, a dinitroaniline herbicide, binds to plant tubulin and inhibits microtubule polymerization in vitro. Planta 1987;172 [2]:252-264.
23. Chan MM-Y, Triemer RE, Fong D. Effect of the anti-microtubule drug oryzalin on growth and differentiation of the parasitic protozoan Leishmania mexicana. Differentiation 1991;46[1]:15-21.
24. Kaidoh T, Nath J, Fujioka H, Okoye V, Aikawa M. Effect and localization of trifluralin in Plasmodium falciparum gametocytes: an electron microscopic study. J Eukaryotic Microbiology. 1995;42 [1]:61-64.
25Stokkermans TJ, Schwartzman JD, Keenan K, Morrissette NS, Tilney LG, Roos DS. Inhibition ofToxoplasma gondii Replication by Dinitroaniline Herbicides. ExpParasitol.1996;84 [3]:355-370.
26. Nath J, Okoye V, Schneider I. Anti-malarial effects of the antitubulin herbicide trifluralin. studies with Plasmodium falciparum. DTIC document. 1994.
Infection Epidemiology and Microbiology
Volume 8, Issue 3
September 2022
Pages 251-258